The hedge fund, named the Pfizer Breakthrough Growth Initiative, seeks to pursue new partnerships by funding biotech companies’ research, manufacturing and growth.
Pfizer’s chief business officer, John Young, noted the need to invest in new therapies amid the pandemic. “There has never been a more important moment to pursue new collaborations in our industry,” he said in the press release.
More articles on pharmacy:
5 recent CMS pharmacy policy changes
Eli Lilly testing COVID-19 drug derived from survivor blood
Some pandemic-inspired FDA changes will stick, commissioner says
